MediciNova reports Phase 2 MN‑001 trial misses primary endpoints but shows HDL improvements
MediciNova disclosed that its Phase 2, double‑blind, placebo‑controlled trial of MN‑001 in patients with non‑alcoholic fatty liver disease and hypertriglyceridemia enrolled 40 participants for 24 weeks and did not achieve statistical significance on the primary endpoints. The study did record statistically significant increases in HDL‑C and HDL‑P and an early reduction in serum triglycerides, with the drug well tolerated and no drug‑related serious adverse events. The company said it will conduct further analyses of the full dataset and remains on track to report topline results for its ALS program (MN‑166) by year‑end.
Why it matters
The missed primary endpoints may delay or reshape the development timeline for MN‑001, affecting investors’ expectations for future revenue from a metabolic‑disease product. The company’s continued focus on the ALS trial signals that MN‑166 remains the primary near‑term catalyst for the stock.
Key facts
- 1The Phase 2 trial enrolled 40 patients and lasted 24 weeks. stocktitan.net
- 2The trial did not achieve statistical significance on its primary endpoints. stocktitan.net
- 3Statistically significant improvements were observed in HDL‑C and HDL‑P versus placebo. stocktitan.net
- 4An early, statistically significant reduction in serum triglycerides was also reported. stocktitan.net
- 5MN‑001 was well tolerated with no drug‑related serious adverse events. stocktitan.net
- 6MediciNova expects topline results for its MN‑166 ALS trial by year‑end. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.